News

Rashmin Savani, MBChB, Head of Scientific Advisory Board, Azome Therapeutics, presented results of preclinical research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform at the 14th conference of the International Society for Hyaluronan Sciences held this week in Portland, Oregon.

Azome Therapeutics, an early stage drug discovery company, announced the appointment of Ulrich H. Von Andrian, MD to its Scientific Advisory Board.  Dr. Von Andrian is the Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology at Harvard Medical School, and Senior Investigator at the Von Andrian Lab at Boston Children's Hospital.

Azome Therapeutics, an early stage drug discovery company, announced the execution of an exclusive US patent license.  Under the agreement, Azome acquired exclusive rights to patent US10562935 entitled “Stapled peptides and uses thereof” and related EU patent applications. The intellectual property includes substantial and specific composition of matter and method of use protection for the company’s core RHAMM antagonist technology platform.